X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
PIRAMAL ENTERPRISES LTD. Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

PIRAMAL ENTERPRISES LTD.  (NCHP)


Here is the latest financial fact sheet of Piramal Healthcare. For more details, see the Piramal Healthcare quarterly results and Piramal Healthcare share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
piramal enterprises - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 2,498.1       No. of shares m 172.56
    Mkt Cap Rs m 431,072       % ch % 1.1
    Vol '000 8.9       % ch week % 6.3
    P/E X 38.4       % ch 1-mth % 34.1
    P/CF X 38.5       % ch 12-mth % 118.2
    EPS (TTM) Rs 65.0       52 week H/L Rs 2,535.0/1,144.0
(As on Apr 28, 2017 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs4866256489491,065 
Low Rs341395483522805 
Sales per share (Unadj.) Rs125.1204.0260.9296.9383.0 
Earnings per share (Unadj.) Rs6.5-13.2-29.1165.255.1 
Diluted earnings per shareRs6.5-13.2-29.1165.255.1 
Cash flow per share (Unadj.) Rs14.0-1.0-14.7182.074.1 
Dividends per share (Unadj.) Rs17.5017.5052.5020.0017.50 
Adj. dividends per shareRs17.5017.5052.5020.0017.50 
Dividend yield (eoy) %4.23.49.32.71.9 
Book value per share (Unadj.) Rs651.5621.4540.2680.1719.9 
Adj. book value per shareRs651.5621.4540.2680.1719.9 
Shares outstanding (eoy) m172.56172.56172.56172.56172.56 
Bonus/Rights/Conversions  PI---- 
Price / Sales ratio x3.32.52.22.52.4 
Avg P/E ratio x64.0-38.7-19.54.517.0 
P/CF ratio (eoy) x29.6-496.3-38.34.012.6 
Price / Book Value ratio x0.60.81.01.11.3 
Dividend payout %270.8-132.9-180.712.131.8 
Avg Mkt Cap Rs m71,35487,99797,583126,901161,344 
No. of employees `0002.93.03.02.43.8 
Total wages/salary Rs m4,3647,96511,37012,94816,898 
Avg. sales/employee Rs Th7,411.211,828.614,969.221,167.817,472.6 
Avg. wages/employee Rs Th1,498.22,676.53,779.85,350.24,466.9 
Avg. net profit/employee Rs Th382.8-763.7-1,666.911,776.72,512.8 
  INCOME DATA
Net Sales Rs m21,58935,20245,02751,22666,099 
Other income Rs m4,7221,7932,2132,5422,425 
Total revenues Rs m26,31136,99447,24053,76868,524 
Gross profit Rs m-94,3176,3918,85518,723 
Depreciation Rs m1,2932,0962,4692,8993,274 
Interest Rs m2,1555,75010,4965,1069,388 
Profit before tax Rs m1,266-1,736-4,3613,3928,485 
Minority Interest Rs m-38-56-833 
Prior Period Items Rs m0-42-311,5931,593 
Extraordinary Inc (Exp) Rs m-57-1911426,962457 
Tax Rs m562486283,4501,032 
Profit after tax Rs m1,115-2,273-5,01428,5009,506 
Gross profit margin %012.314.217.328.3 
Effective tax rate %4.4-14.3-14.4101.712.2 
Net profit margin %5.2-6.5-11.155.614.4 
  BALANCE SHEET DATA
Current assets Rs m16,77440,87642,32449,22047,488 
Current liabilities Rs m25,52081,51593,50852,518104,362 
Net working cap to sales %-40.5-115.4-113.7-6.4-86.0 
Current ratio x0.70.50.50.90.5 
Inventory Days Days7956534841 
Debtors Days Days7462585951 
Net fixed assets Rs m15,01320,76822,58521,03126,532 
Share capital Rs m345345345345345 
"Free" reserves Rs m110,986105,09189,562112,613114,024 
Net worth Rs m112,420107,23693,211117,359124,221 
Long term debt Rs m6,48211,61026,79637,87575,812 
Total assets Rs m147,496202,521215,045209,358308,356 
Interest coverage x1.60.70.61.71.9 
Debt to equity ratio x0.10.10.30.30.6 
Sales to assets ratio x0.10.20.20.20.2 
Return on assets %2.21.72.516.16.1 
Return on equity %1.0-2.1-5.424.37.7 
Return on capital %2.83.15.123.910.0 
Exports to sales %30.222.721.519.517.2 
Imports to sales %13.210.49.38.56.6 
Exports (fob) Rs m6,5157,9879,68710,00911,362 
Imports (cif) Rs m2,8513,6664,2094,3744,364 
Fx inflow Rs m7,0468,89110,51712,01014,435 
Fx outflow Rs m3,4184,3395,0065,7405,183 
Net fx Rs m3,6274,5525,5106,2709,253 
  CASH FLOW
From Operations Rs m -6,848 -15,705 -16,044 -22,069 -67,773 
From Investments Rs m -15,818 -16,645 14,829 61,771 -8,768 
From Financial Activity Rs m 6,402 32,807 1,258 -38,646 76,199 
Net Cashflow Rs m -16,264 458 43 1,056 -342 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for piramal enterprises ltd.

 Share Holding
Indian Promoters : 52.9%
Foreign collaborators : 0.0%
Indian inst/Mut Fund : 4.0%
FIIs : 26.6%
ADR/GDR : 0.0%
Free float : 16.5%
Shareholders : 93,274
Pledged promoter(s) holding : 0.0%
 Company Information
Top
    REGD OFF: Piramal Tower, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400 013
    E-MAIL: complianceofficer.phl@piramal.com     WEB: www.piramal.com
    TELEPHONE: (022) 3046 7839     FAX: (022) 3046 7855
    SECTOR: PHARMACEUTICALS     GROUP: AJAY PIRAMAL
    TR AGENT: Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
    AUDITOR: Price Waterhouse
CHM: Ajay G. Piramal COMP SEC: Leonard D' Souza YEAR OF INC: 1947 BSE CODE: 500302 FV (Rs): 2 DIV YIELD (%): 0.7

More pharmaceuticals Company Fact Sheets:   INDOCO REMEDIESFRESENIUS KABI ONCO.AUROBINDO PHARMAMERCK LTDFULFORD INDIA


Today's Market

Global Markets Ends the Week Higher on the Back of French Election Results(RoundUp)

Financial markets received a boost earlier in the week by news that centrist Emmanuel Macron had triumphed over far-right candidate Marine Le Pen in the first round of France's presidential election.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

We Don't Want More F&O Stocks... We Need Smaller Lot Sizes(Daily Profit Hunter)

Apr 26, 2017

Are you excited to trade in the sixteen new stocks to be introduced in the F&O segment this Friday?

Our Private Class with India's Value Investing Guru(The 5 Minute Wrapup)

Apr 19, 2017

Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.

HDFC Bank: The Solid Outperformer(Chart Of The Day)

Apr 22, 2017

Why HDFC Bank beat the Sensex by nearly 3 times.

In an Ocean of Corporate Defaulters, Vijay Mallya is a Small Fish(Vivek Kaul's Diary)

Apr 20, 2017

While it is important to get Mallya back to India, the government needs to show the same vigour in chasing defaulters of public sector bank loans residing in India.

4 Ways GST Will Impact The Mutual Fund Industry(Outside View)

Apr 19, 2017

PersonalFN explains how GST would impact India's mutual fund industry and investors

More

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - ASTRAZENECA PHARMA COMPARISON

Compare Company With Charts

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS